Therapeutic applications of incretin mimetics for metabolic diseases: Preclinical studies

Christine Mack, Kevin Laugero, Que Liu, Carolyn Jodka, Andrew Young, David Parkes

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Exenatide (exendin-4) is an incretin mimetic peptide that shares several glucoregulatory actions with the endogenous incretin GLP-1. In addition to its actions on glucose control, exenatide produces effects to reduce food intake and body weight in all species studied. GLP-1 and exenatide have also been shown to modulate cardiovascular function in both animal and human studies. This overview examines the metabolic effects of exenatide beyond its antidiabetic actions, and will focus on studies with respect to obesity, hypertension, and cardiac dysfunction in preclinical models of diet-induced obesity, metabolic syndrome, and chronic heart failure.

Original languageEnglish (US)
Pages (from-to)553-558
Number of pages6
JournalDrug Development Research
Issue number7
StatePublished - Jul 2006
Externally publishedYes


  • Exenatide
  • GLP-1
  • Heart failure
  • Hypertension
  • Obesity

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology


Dive into the research topics of 'Therapeutic applications of incretin mimetics for metabolic diseases: Preclinical studies'. Together they form a unique fingerprint.

Cite this